STOCK TITAN

T. Rowe Price discloses 2.7% Hologic (HOLX) stake in Schedule 13G/A

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting its beneficial ownership of Hologic, Inc. common stock as of December 31, 2025.

The firm reports beneficial ownership of 5,932,301 shares of Hologic common stock, representing 2.7% of the class. It has sole power to vote 5,914,773 shares and sole power to dispose of 5,932,301 shares, with no shared voting or dispositive power.

The filer states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Hologic. It also expressly denies that this filing should be construed as an admission of beneficial ownership of the reported securities.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Investment Management, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:02/17/2026

FAQ

What stake in Hologic (HOLX) does T. Rowe Price report in this Schedule 13G/A?

T. Rowe Price Investment Management reports beneficial ownership of 5,932,301 shares of Hologic common stock, representing 2.7% of the class as of December 31, 2025. This reflects a holding below the 5% threshold for large shareholders.

What voting power does T. Rowe Price have over Hologic (HOLX) shares?

T. Rowe Price reports sole voting power over 5,914,773 shares of Hologic common stock and no shared voting power. This means it alone can vote those shares, while no other party is reported to share voting authority.

What dispositive power does T. Rowe Price report for its Hologic (HOLX) position?

T. Rowe Price reports sole dispositive power over 5,932,301 shares and no shared dispositive power. Dispositive power indicates the authority to sell or otherwise dispose of the shares on behalf of clients or accounts.

Is T. Rowe Price’s Hologic (HOLX) holding intended to influence control of the company?

The filer states the Hologic shares were acquired and are held in the ordinary course of business and not for changing or influencing control. It also notes the position is not held in connection with any control-related transaction.

Why does the Schedule 13G/A for Hologic (HOLX) mention ownership of 5 percent or less?

The filing includes an item indicating ownership of 5 percent or less of the class. This confirms T. Rowe Price’s reported 2.7% stake falls below the 5% level often associated with larger institutional shareholders.

Does T. Rowe Price admit beneficial ownership of the Hologic (HOLX) shares reported?

T. Rowe Price explicitly states that this filing should not be construed as an admission that it is the beneficial owner of the reported Hologic shares. It affirmatively denies beneficial ownership, despite reporting the position for regulatory purposes.